Ayala Pharmaceuticals, Inc. (AYLA)

NASDAQ: AYLA · IEX Real-Time Price · USD
1.15
+0.06 (5.49%)
Jul 6, 2022 9:30 AM EDT - Market open

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 2021202020192018
Revenue
3.513.712.330
Revenue Growth (YoY)
-5.45%58.87%--
Cost of Revenue
-3.51-3.711.290
Gross Profit
7.017.421.050
Selling, General & Admin
9.287.374.343.29
Research & Development
29.9422.4114.425.74
Operating Expenses
39.2229.7818.769.04
Operating Income
-32.21-22.36-17.71-9.04
Interest Expense / Income
0.26-0.0600
Other Expense / Income
7.017.42-0.23-0.45
Pretax Income
-39.48-29.72-17.49-8.59
Income Tax
0.780.430.310.29
Net Income
-40.25-30.15-17.79-8.87
Net Income Common
-40.25-30.15-17.79-8.87
Shares Outstanding (Basic)
141055
Shares Outstanding (Diluted)
14105-
Shares Change
46.02%98.02%--
EPS (Basic)
-2.80-3.06-3.57-1.80
EPS (Diluted)
-2.80-3.06-3.57-
Free Cash Flow Per Share
-2.66-2.80-3.27-1.34
Gross Margin
200.00%200.00%44.94%-
Operating Margin
-918.60%-603.05%-758.83%-
Profit Margin
-1148.15%-813.00%-762.30%-
Free Cash Flow Margin
-1094.15%-743.96%-697.51%-
Effective Tax Rate
-1.97%-1.43%-1.75%-3.33%
EBITDA
-39.05-29.6-17.34-8.54
EBITDA Margin
-1113.81%-798.14%-742.76%-
Depreciation & Amortization
0.170.180.150.05
EBIT
-39.22-29.78-17.49-8.59
EBIT Margin
-1118.60%-803.05%-749.19%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).